Abstract
The therapeutic approaches for non-small cell lung cancer (NSCLC) patients with solitary bone metastases include surgery, radiotherapy, chemotherapy and so on. Recently, molecular targeted therapy such as the Denosumab has become a new option. Though there are so many options, the outcomes of the NSCLC with bone metastases are not so good. But for those with solitary bone metastases, radical treatment is necessary to improve the survival time and prognosis. Key words: Bone neoplasms; Carcinoma, non-small-cell lung; Radiotherapy; Antineoplastic agents; Surgical procedures, operative
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.